Increasing Incidence of Pemphigus Vulgaris Driving Europe Pemphigus Vulgaris Treatment Market at 8.10% CAGR During 2025-30

• Overview
• Table of Content
• Research Methodology
• Download Free Sample

The Europe Pemphigus Vulgaris Treatment Market size was valued at around USD106.15 million in 2024 and is expected to reach USD169.38 million by 2030. Along with this, the market is estimated to grow at a CAGR of around 8.10% during the forecast period, i.e., 2025-30, cites MarkNtel Advisors in the recent research report. The market growth is driven by several factors, including the rising cases of autoimmune diseases such as Pemphigus Vulgaris (PV) in the countries of Europe such as Germany, France, the United Kingdom, Italy, and many more, the resilient research and developments in the region, substantial funding backed by the European governments, the advancements in PV treatments and therapies including biomarkers and biologics, etc. The prime stimulating factors for the high prevalence of PV are genetic susceptibility, including the transfer of the HLA gene, environmental risks, and many more. These are significantly increasing the risk of PV in European countries.

Additionally, various national governments of this region are proactively encouraging clinical trials for the identification of advanced treatments for autoimmune diseases such as PV by investing substantially in related projects. These kinds of efforts are increasing the market growth and providing many opportunities for the market to further grow in the region. Also, the treatments that include biologics are gaining momentum in this market due to having high quality, safety, and efficacy. Moreover, the convenience and trust related to hospital pharmacies make them a preferred distribution channel in this regional market.

Furthermore, the discoveries related to enhanced medications, such as biomarker therapy and personalized treatments for PV, are uplifting the market due to widespread adoption and better patient outcomes. However, the complexity of the biologics drugs manufacturing processes, including the requirement for a controlled environment, the high costs of treatment, the fragmented value chains, etc., are hindering the market growth & expansion, further states the research report, “Europe Pemphigus Vulgaris Treatment Market Analysis, 2025.”

Segmentation Analysis

Biologics Treatment Type Holds the Largest Market Share

Based on the treatment type, the market is further bifurcated into Corticosteroids, Immunosuppressants, Biologics, Antibiotics, and Plasmapheresis. Among all, the biologics segment holds the largest market share of about 40%. These are technically advanced solutions over conventional medications, such as immunosuppressants, etc., for the treatment of autoimmune diseases such as Pemphigus Vulgaris. The treatment is associated with better patient outcomes and is highly effective due to its ability to completely remove the root cause of these diseases, along with fewer side effects. As a result, the customers are highly preferring this as a treatment for PV.

Additionally, rituximab is one of the dominant biologics in Europe, which recently got approved by the regulatory body called the European Medicines Agency (EMA). It has treated over 80 percent of individuals suffering from Pemphigus Vulgaris in European countries. Moreover, other biologics such as Intravenous Immunoglobulin (IVIG) AND FcRn inhibitors are gaining momentum in the European PV Industry.

Germany is the Most Preferred Destination for Pemphigus Vulgaris Treatment

Germany is leading the European Pemphigus Vulgaris Treatment Industry and holds a market share of about 28%. The dominance is due to the strong presence of advanced healthcare infrastructure in the country over other European countries, and Germany is the only European country that highly invests in the healthcare sector by more than 10%, which is higher than the average investment of the whole European Union. Moreover, Germany has the largest number of hospitals with advanced medical devices in Europe, which is also driving the Pemphigus Vulgaris Treatment Industry in the country.

Additionally, Germany has the highest number of biotech pharmacies compared to other countries in this region, which is contributing to the dominance of this country in the regional market. Moreover, Germany has high patient awareness, which is increasing the value of the latest treatments for PV and ultimately increasing the growth of the market. Moreover, due to strong reimbursement systems, including health insurance systems, the adoption has increased, and the market is significantly growing.

Competitive Landscape

With strategic initiatives, such as mergers, collaborations, and acquisitions, the leading market companies, including Roche Holding AG, GlaxoSmithKline plc, Pfizer Inc., Novartis AG, Sanofi S.A., Johnson & Johnson (Janssen Pharmaceuticals), AstraZeneca plc, Amgen Inc., UCB S.A., and others are looking forward to strengthening their market positions.

Key Questions Answered in the Research Report

1. What are the industry’s overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares)?
2. What are the trends influencing the current scenario of the market?
3. What key factors would propel and impede the industry across the region?
4. How has the industry been evolving in terms of geography & service adoption?
5. How has the competition been shaping up across various countries?
6. How have buying behavior, customer inclination, and expectations from service providers been evolving during 2020-30?
7. Who are the key competitors, and what strategic partnerships or ventures are they coming up with to stay afloat during the projected time frame?